Kyowa Hakko Kirin Co Ltd (4151.T) Key Developments | Reuters.com
Edition:
United States

Kyowa Hakko Kirin Co Ltd (4151.T)

4151.T on Tokyo Stock Exchange

1,726JPY
1 Jul 2016
Change (% chg)

¥-10 (-0.58%)
Prev Close
¥1,736
Open
¥1,731
Day's High
¥1,741
Day's Low
¥1,709
Volume
1,590,000
Avg. Vol
1,458,306
52-wk High
¥2,321
52-wk Low
¥1,497

Latest Key Developments (Source: Significant Developments)

Medgenics enters collaboration with Kyowa Hakko Kirin
Monday, 6 Jun 2016 07:00am EDT 

Medgenics Inc : Entered collaboration with Kyowa Hakko Kirin Co Ltd for development and commercialization of Kyowa Hakko's anti-light monoclonal antibody . Data from signal finding study in severe pediatric onset inflammatory bowel disease patients expected in first half 2017 . Upon completion of signal finding study in severe pediatric onset IBD, company will have option to license rights to develop program . Following exercise of option, medgenics will make a one-time, upfront payment in low single-digit millions to Kyowa Hakko Kirin .Co to have commercialization rights in U.S., Canada, will also add rights in europe if Kyowa Hakko Kirin selects licensing arrangement.  Full Article

Kyowa Hakko Kirin announces Fujifilm Kyowa Kirin Biologics establishes joint venture with AstraZeneca to develop and commercialise anti-VEGF biosimilar
Friday, 24 Jul 2015 02:00am EDT 

Kyowa Hakko Kirin Co Ltd:Fujifilm Kyowa Kirin Biologics has entered into an agreement with AstraZeneca plc to establish a joint venture in UK for the development and commercialisation of FKB238 in development for the treatment of multiple solid tumours.Fujifilm Kyowa Kirin Biologics and AstraZeneca to hold 50 pct stake in the JV respectively, and the JV with registered capital of $90 mln.  Full Article

Kyowa Hakko Kirin raises consolidated mid-year and full-year outlook for FY 2015
Friday, 24 Jul 2015 02:00am EDT 

Kyowa Hakko Kirin Co Ltd:Says the company raised the consolidated mid-year outlook for the FY ending Dec. 2015.Revenue forecast increased to 178,800 million yen from 172,000 million yen.Operating profit forecast increased to 22,400 million yen from 16,500 million yen.Says the company raised the consolidated full-year outlook for the FY ending Dec. 2015.Revenue forecast increased to 360,000 million yen from 354,000 million yen.Operating profit forecast increased to 47,000 million yen from 41,500 million yen.Ordinary profit forecast increased to 41,000 million yen from 34,000 million yen.Net profit forecast increased to 26,000 million yen from 18,500 million yen.Earnings per share forecast increased to 47.51 yen from 33.80 yen.Comments that increased sales and decreased investment loss and corporate tax are the main reasons for the forecast.  Full Article

R&I affirms Kyowa Hakko Kirin's rating at "A+" and announces stable outlook
Thursday, 16 Jul 2015 02:00am EDT 

Kyowa Hakko Kirin Co Ltd:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+".Rating outlook stable.  Full Article

Kyowa Hakko Kirin Co Ltd and Syndax Pharmaceuticals Inc announces license agreement to develop and commercialize Entinostat in Japan and Korea
Wednesday, 7 Jan 2015 07:00pm EST 

Kyowa Hakko Kirin Co Ltd and Syndax Pharmaceuticals Inc:Says that the companies have entered into a license agreement for the exclusive rights to develop and commercialize entinostat in Japan and Korea.Entinostat is a Class I selective histone deacetylase (HDAC) inhibitor being developed by Syndax in the United States and Europe in combination with hormone therapy for advanced breast cancer and immune therapy combinations in solid tumors.Under the terms of the agreement, Kyowa Hakko Kirin will pay Syndax a total of up to $100 million including an upfront fee of $25 million with a certain amount of an equity investment and potential development and commercial milestone payments.Syndax will manufacture and supply the product to Kyowa Hakko Kirin during the term of the agreement.  Full Article

ONO PHARMACEUTICAL CO LTD, Bristol-Myers Squibb and Kyowa Hakko Kirin announces Immuno-Oncology Clinical collaboration studying Opdivo (nivolumab) and Mogamulizumab in Advanced Solid Tumors
Wednesday, 10 Dec 2014 06:00am EST 

ONO PHARMACEUTICAL CO LTD, Bristol-Myers Squibb Co and Kyowa Hakko Kirin Co Ltd:Enters into a clinical trial collaboration agreement to conduct a Phase 1 combination study with Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor, and mogamulizumab, an anti-CCR4 antibody.Study will focus on evaluating the safety, tolerability and anti-tumor activity of combining Opdivo and mogamulizumab as a potential treatment option for patients with advanced or metastatic solid tumors.Study will be conducted by Ono and Kyowa Hakko Kirin.Additional details of the collaboration were not disclosed.  Full Article

Kyowa Hakko Kirin Co Ltd subsidiary completes fully acquire Archimedes Pharma
Tuesday, 5 Aug 2014 08:00pm EDT 

Kyowa Hakko Kirin Co Ltd:UK-based subsidiary ProStrakan Group plc completed fully acquire Archimedes Pharma on Aug. 5 (UK time), Archimedes Pharma became wholly owned subsidiary of ProStrakan Group plc as the result.Plan disclosed on July 11.  Full Article

BRIEF-Medgenics enters collaboration with Kyowa Hakko Kirin

* Entered collaboration with Kyowa Hakko Kirin Co Ltd for development and commercialization of Kyowa Hakko's anti-light monoclonal antibody